3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
91
Neoplasm Metastasis
11
Prostate Cancer Metastatic
4
Oligometastatic Prostate Cancer
3
Adenocarcinoma
3
Radiation Injuries
2
Prostatic Diseases
2
Prostate CA
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Urologic Diseases
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
PSA Level Greater Than 0.03
1
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Insulin Resistance
1
Hormone Sensitive Prostate Cancer
1
Genital Diseases, Male
1
Interventions
Cystectomy
2
testosterone 17 beta-cypionate
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Stents
1
Standard of Care
1
Radiosurgery
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Diseases
×
Androgen Antagonists
×
Clear all
NCT07483658
2026-03-19
HYP-OP-RT
CHU de Quebec-Universite Laval
Phase NA
Not yet recruiting
434 enrolled